Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -170.55% is 176% below its 5-year average of -61.72%, near the low end of its 5-year range (-170.55%–-24.26%).
As of the fiscal period ended Tuesday, June 30, 2026. 46.87% below its 12-month average of -116.12%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -170.55%.
RETURN ON EQUITY (ROE)
-170.55%
RETURN ON EQUITY (ROE) AVG TTM
-116.12%
RETURN ON EQUITY (ROE) AVG 3Y
-70.66%
RETURN ON EQUITY (ROE) AVG 5Y
-61.72%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-46.87%
CURRENT VS 3Y AVG
-141.36%
CURRENT VS 5Y AVG
-176.33%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-305.98%
vs the sector median at left
TScan Therapeutics, Inc.
Market Cap
$16.82M
Return on Equity (ROE)
-170.55%
TTM Avg
-116.12%
3Y Avg
-70.66%
5Y Avg
-61.72%
Market Cap
$16.84M
Return on Equity (ROE)
-71.57%
TTM Avg
-65.12%
3Y Avg
-85.39%
5Y Avg
-90.29%
Market Cap
$16.74M
Return on Equity (ROE)
-125.30%
TTM Avg
118.50%
3Y Avg
7030.24%
5Y Avg
4638.47%
Market Cap
$16.64M
Return on Equity (ROE)
-101.76%
TTM Avg
-188.04%
3Y Avg
-167.76%
5Y Avg
-134.95%
Market Cap
$17.07M
Return on Equity (ROE)
-34.50%
TTM Avg
-796.82%
3Y Avg
-138.82%
5Y Avg
-407.45%
Market Cap
$16.52M
Return on Equity (ROE)
N/A
TTM Avg
-416.37%
3Y Avg
-259.03%
5Y Avg
-190.00%
Market Cap
$17.31M
Return on Equity (ROE)
-54.45%
TTM Avg
-33.23%
3Y Avg
-44.23%
5Y Avg
-52.50%
Market Cap
$17.39M
Return on Equity (ROE)
-117.98%
TTM Avg
-84.94%
3Y Avg
-64.05%
5Y Avg
-76.29%
Market Cap
$15.78M
Return on Equity (ROE)
-271.81%
TTM Avg
-934.34%
3Y Avg
-347.56%
5Y Avg
-265.02%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TScan Therapeutics, Inc. (TCRX) | $16.82M | -170.55% | -116.12% | -70.66% | -61.72% |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | -71.57% | -65.12% | -85.39% | -90.29% |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | -125.30% | 118.50% | 7030.24% | 4638.47% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | -101.76% | -188.04% | -167.76% | -134.95% |
| PAVmed Inc. (PAVM)vs › | $17.07M | -34.50% | -796.82% | -138.82% | -407.45% |
| Dyadic International, Inc. (DYAI)vs › | $16.52M | N/A | -416.37% | -259.03% | -190.00% |
| Lipocine Inc. (LPCN)vs › | $17.31M | -54.45% | -33.23% | -44.23% | -52.50% |
| Cosmos Health Inc. (COSM)vs › | $17.39M | -117.98% | -84.94% | -64.05% | -76.29% |
| BioCardia, Inc. (BCDA)vs › | $15.78M | -271.81% | -934.34% | -347.56% | -265.02% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.68M | -348.81% | -160.92% | -184.71% | -151.29% |
ROE
-170.6%
ROA
-68.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -170.55% |
| 2026-03-31 | -128.25% |
| 2025-12-31 | -105.40% |
| 2025-09-30 | -99.01% |
| 2025-06-30 | -77.40% |
| 2025-03-31 | -62.55% |
| 2024-12-31 | -52.91% |
| 2024-09-30 | -48.59% |
| 2024-06-30 | -40.91% |
| 2024-03-31 | -78.72% |
| 2023-12-31 | -59.14% |
| 2023-09-30 | -52.28% |
| 2023-06-30 | -42.80% |
| 2023-03-31 | -93.09% |
| 2022-12-31 | -66.60% |
| 2022-09-30 | -52.89% |
| 2022-06-30 | -46.56% |
| 2022-03-31 | -39.03% |
| 2021-12-31 | -30.24% |
| 2021-09-30 | -24.26% |
| 2021-06-30 | -33.77% |
| 2021-03-31 | -26.03% |
